Vicore Pharma Holding AB 2024 AR2
The report highlights Vicore Pharma Holding AB's strategic and operational progress during the fiscal year 2024, focusing on the clinical development of its lead drug candidate, buloxibutid, for idiopathic pulmonary fibrosis (IPF). Key achievements included the initiation of the global Phase 2b ASPIRE trial, positive final results from the Phase 2a AIR trial, and an exclusive licensing agreement with Nippon Shinyaku for development in Japan. Financially, the company strengthened its position by raising over SEK 880 million in financing transactions. On the sustainability front, Vicore became a participant in the UN Global Compact and integrated ESG screening criteria into its procurement processes.
Company: Vicore Pharma Holding AB
Sector: Health Care
Country: Sweden
Year: 2024
Type: AR2
Pages: 76
Vicore Pharma Holding AB
Annual Report
The report highlights Vicore Pharma Holding AB's strategic and operational progress during the fiscal year 2024, focusing on the clinical development of its lead drug candidate, buloxibutid, for idiopathic pulmonary fibrosis (IPF). Key achievements included the initiation of the global Phase 2b ASPIRE trial, positive final results from the Phase 2a AIR trial, and an exclusive licensing agreement with Nippon Shinyaku for development in Japan. Financially, the company strengthened its position by raising over SEK 880 million in financing transactions. On the sustainability front, Vicore became a participant in the UN Global Compact and integrated ESG screening criteria into its procurement processes.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Jan 1, 2024 - Dec 31, 2024
Fiscal Year
2024
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Women on Board
Women in Management
Workplace Fatalities
Employees